Vanguard Pharmaceutical Corporation Forms Team in Peru

SAN ANTONIO, TX, Jan 07 (MARKET WIRE) --
Vanguard Pharmaceutical Corp. (PINKSHEETS: VGPH), a company who has
joined the fight against cancer by selling affordable generic oncology
drugs and researching noninvasive cures for cancer has recently visited
Lima, Peru to form a sales and marketing team and conduct further
research on the market.

Vanguard's president, Raul Fernandez, was pleased with the business trip
stating, "We believe we have found the key people who have the experience
to ensure our success in the Peruvian oncology market." The newly formed
team has three members with significant experience in the field. Mr.
Rodriguez has almost 50 years of pharmaceutical management experience
often overseeing the introduction and promotion of new pharmaceutical
products. Mr. Pando has 35 years experience in the industry and 20 years
experience in the oncology field. He has worked as a product specialist
advising professionals in the field on oncology drugs. Mr. Rodriguez's
son, Ernesto has also worked 5 years in pharmaceutical sales and
promotions and will also be a strong player to the team.

www.vanguardpharm.com

About Vanguard Pharmaceutical

In an era of aging populations, rising health care costs, and increasing
cancer cases Vanguard's mission is to decrease health care expenditures by
selling affordable oncology and generic drugs and by investing in research
to find a noninvasive cure for cancer.

Generic medicines allow patients to access safe, effective, high-quality
medicines at 10%-80% of the price of branded originator medicines. In this
way, generic medicines support the sustainability of health care provision
and contribute to controlling pharmaceutical expenditure. Vanguard is
currently targeting Latin America for its oncology and generic
pharmaceutical sales as it is believed to have a substantially unmet
demand for advanced generics and entry into the market can be done with
relative ease. Latin America is set to emerge as a globally significant
market and its generics market is conservatively expected to reach US$6.4
billion by the year-end of 2009.

A noninvasive cure for cancer will revolutionize our health care system by
highly reducing hospital stays as patients will not have to go through
life threatening chemotherapy and radiation which could save health care
systems billions of dollars. Vanguard's team is researching several new
technologies such as telomerase inhibitor therapy, nanoparticle therapies,
and low power radio frequency radiation. Vanguard plans to partner with
established clinical centers and universities to further develop these
technologies then license them out. It has also discussed performing
trials in Latin American oncology centers.

Forward-Looking Statements

This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements in this release that are forward-looking statements are based
on current expectations and assumptions that are subject to known and
unknown risks, uncertainties, or other factors which may cause actual
results, performance, or achievements of the company to be materially
different from any future results, performance, or achievements expressed
or implied by such forward-looking statements. Actual results could
differ materially because of factors such as the effect of general
economic and market conditions, entry into markets with vigorous
competition, market acceptance of new products and services, continued
acceptance of existing products and services, technological shifts, and
delays in product development and related product release schedules, any
of which may cause revenues and income to fall short of anticipated
levels. All information in this release is as of the date of this
release. The company undertakes no duty to update any forward-looking
statement to conform the statement to actual results or changes in the
company's expectations.

Contact:
Raul Fernandez
210-215-4633
President
Vanguard Pharmaceutical Corp.
www.vanguardpharm.com

Copyright 2009, Market Wire, All rights reserved.

-0-